| scholarly article | Q13442814 |
| P50 | author | José Saura-Esteller | Q64001843 |
| Daniel Iglesias-Serret | Q39031912 | ||
| P2093 | author name string | Ana M Cosialls | |
| Diana M González-Gironès | |||
| Gabriel Pons | |||
| Joan Gil | |||
| Fernando Albericio | |||
| Rodolfo Lavilla | |||
| Esmeralda de la Banda | |||
| Helena Pomares | |||
| Sara Preciado | |||
| Eva M González-Barca | |||
| Sonia Núñez-Vázquez | |||
| P2860 | cites work | Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib | Q27853011 |
| A trifluorinated thiazoline scaffold leading to pro-apoptotic agents targeting prohibitins | Q28247417 | ||
| Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity | Q28268312 | ||
| A novel prohibitin-binding compound induces the mitochondrial apoptotic pathway through NOXA and BIM upregulation | Q28269042 | ||
| The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2 | Q28275561 | ||
| Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes | Q44274481 | ||
| Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells. | Q53218427 | ||
| Prohibitin expression is increased in phorbol ester-treated chronic leukemic B-lymphocytes | Q31853290 | ||
| Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study | Q33404763 | ||
| Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients | Q33821990 | ||
| Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial | Q34141305 | ||
| Regulation of Syk by phosphorylation on serine in the linker insert | Q34400900 | ||
| Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling | Q34599670 | ||
| Prohibitin and mitochondrial biology | Q35001369 | ||
| Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells | Q35852684 | ||
| Ibrutinib resistance in chronic lymphocytic leukemia | Q35881570 | ||
| Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 | ||
| The role and therapeutic potential of prohibitin in disease | Q36018450 | ||
| The BCL-2 protein family, BH3-mimetics and cancer therapy | Q36067778 | ||
| An interconnected hierarchical model of cell death regulation by the BCL-2 family | Q36109186 | ||
| Initial treatment of CLL: integrating biology and functional status | Q36219647 | ||
| Prohibitins and the cytoplasmic domain of CD86 cooperate to mediate CD86 signaling in B lymphocytes. | Q36514204 | ||
| Rapid induction of apoptosis in chronic lymphocytic leukemia cells by the microtubule disrupting agent BNC105. | Q36844333 | ||
| The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo | Q37187540 | ||
| Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells. | Q37470898 | ||
| Prohibitins and the functional compartmentalization of mitochondrial membranes. | Q37627477 | ||
| The IgM antigen receptor of B lymphocytes is associated with prohibitin and a prohibitin-related protein | Q37635432 | ||
| From pathogenesis to treatment of chronic lymphocytic leukaemia | Q37643423 | ||
| Targeting prohibitins induces apoptosis in acute myeloid leukemia cells. | Q37662175 | ||
| Prohibitin ligands in cell death and survival: mode of action and therapeutic potential | Q38092225 | ||
| Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment | Q38110472 | ||
| The molecular pathogenesis of chronic lymphocytic leukaemia | Q38748645 | ||
| BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. | Q38776895 | ||
| Front-line treatment of CLL in the era of novel agents | Q39084142 | ||
| Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. | Q39416260 | ||
| Fludarabine nucleoside modulates nuclear "survival and death" proteins in resistant chronic lymphocytic leukemia cells | Q39434653 | ||
| AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells. | Q39674990 | ||
| Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. | Q40127987 | ||
| Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways | Q40315433 | ||
| Chronic lymphocytic leukemia development is accelerated in mice with deficiency of the pro-apoptotic regulator NOXA. | Q42384351 | ||
| P433 | issue | 9 | |
| P921 | main subject | chronic lymphocytic leukemia | Q1088156 |
| ibrutinib | Q5984881 | ||
| P304 | page(s) | 1587-1593 | |
| P577 | publication date | 2017-06-15 | |
| P1433 | published in | Haematologica | Q5638209 |
| P1476 | title | The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax | |
| P478 | volume | 102 |
| Q55253157 | Significance of prohibitin domain family in tumorigenesis and its implication in cancer diagnosis and treatment. |
| Q50158386 | The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells ex vivo but fails to prevent leukemia development in a murine model |
Search more.